# Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)

> **NCT00831545** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 162 (actual)

## Conditions studied

- Metastases of Central Nervous System
- Melanoma
- Breast Neoplasm
- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00831545
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-12-01
- **Primary completion:** 2006-10-20
- **Final completion:** 2006-10-20
- **Target enrollment:** 162 (ACTUAL)
- **Last updated:** 2017-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00831545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00831545, "Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00831545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*